Amphotéricine B liposomale en première intention dans la leishmaniose viscérale infantile en région Provence-Alpes-Côte-d'Azur-Corse

Conclusion. - Liposomal amphotericin B treatment is usual for children referred for visceral leishmaniasis in this region. This treatment may be approved regarding the high level of effectiveness and the low number of adverse events. A two days drug regimen with 20 mg/kg should be evaluated. Moreover, the incidence of the pediatric visceral leishmaniasis in southern France is decreasing, but local variations may be observed.